Matinas BioPharma Holdings, Inc. operates as a clinical-stage biopharmaceutical company focused on identifying and developing effective anti-fungal and anti-bacterial therapeutics for the treatment of serious or life threatening infections.

Current Report (Form 8-K | Period ending 2025-11-18)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Matinas Biopharma Holdings I (MTNB US)

Current Report (Form 8-K | Period ending 2025-11-18)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-08-15)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-08-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)